Cytek Biosciences, Inc.
CTKB
$3.71
$0.195.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 57.48M | 51.50M | 46.62M | 44.86M | 58.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.48M | 51.50M | 46.62M | 44.86M | 58.23M |
| Cost of Revenue | 23.82M | 22.50M | 21.18M | 21.85M | 25.19M |
| Gross Profit | 33.65M | 29.01M | 25.44M | 23.01M | 33.05M |
| SG&A Expenses | 23.54M | 23.37M | 23.96M | 23.95M | 22.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.09M | 55.75M | 55.14M | 55.59M | 58.37M |
| Operating Income | 386.00K | -4.25M | -8.53M | -10.73M | -137.00K |
| Income Before Tax | 10.32M | 157.00K | -7.19M | -8.99M | 4.11M |
| Income Tax Expenses | 680.00K | -784.00K | 3.25M | -2.82M | -1.39M |
| Earnings from Continuing Operations | 9.64M | 941.00K | -10.43M | -6.17M | 5.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.64M | 941.00K | -10.43M | -6.17M | 5.50M |
| EBIT | 386.00K | -4.25M | -8.53M | -10.73M | -137.00K |
| EBITDA | 2.24M | -2.40M | -6.72M | -9.04M | 1.49M |
| EPS Basic | 0.07 | 0.01 | -0.08 | -0.05 | 0.04 |
| Normalized Basic EPS | 0.04 | 0.00 | -0.03 | -0.04 | 0.02 |
| EPS Diluted | 0.07 | 0.01 | -0.08 | -0.05 | 0.04 |
| Normalized Diluted EPS | 0.04 | 0.00 | -0.03 | -0.04 | 0.02 |
| Average Basic Shares Outstanding | 129.08M | 131.00M | 131.44M | 130.92M | 133.54M |
| Average Diluted Shares Outstanding | 129.08M | 132.79M | 131.44M | 130.92M | 133.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
